What is avoMD?
AvoMD operates as an AI platform designed for healthcare enterprises, aiming to infuse trusted knowledge into clinical copilots. The platform processes medical guidelines, payer information, and patient data within the Electronic Health Record (EHR) system to facilitate more informed clinical decisions. It automates end-to-end workflows across charting, documentation improvement, discharge planning, and ordering, transforming EHRs into intelligent systems of action. This enhances clinical outcomes and conserves valuable clinician time, positioning AvoMD at the forefront of healthcare innovation.
How much funding has avoMD raised?
avoMD has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2026): $10M with participation from AlleyCorp companies, Las Olas VC, Noro-Moseley Partners, and Medmountain Ventures
Key Investors in avoMD
AlleyCorp companies
AlleyCorp is a company that focuses on building and investing in transformative businesses. They are comprised of tech pioneers, investors, and entrepreneurs dedicated to creating impactful solutions for both the present and future. Their portfolio includes a variety of innovative companies across different sectors. AlleyCorp aims to support and nurture the growth of these transformative companies.
Las Olas VC
Las Olas Venture Capital is a venture capital firm that focuses on backing founders who are developing AI and software applications aimed at modernizing outdated business workflows. They typically invest between $1.5 million and $3 million in seed-stage companies, with a preference for SaaS and vertical AI industries. The firm emphasizes hands-on support to help these startups achieve measurable ROI and efficiency gains. Their target clients are exceptional founding teams looking to innovate and improve productivity in their respective markets.
Noro-Moseley Partners
Noro-Moseley Partners specializes in early growth equity investments for rapidly-scaling B2B technology and healthcare companies. Since 1983, they have partnered with exceptional CEOs to help scale high-growth businesses, focusing on sustainable economic models. Their investment criteria include year-over-year growth of 50% or more and target revenue run rates between $2 million and $20 million. The firm is dedicated to delivering managed detection and response services and best-in-class infusion therapy in underserved markets.
What's next for avoMD?
The substantial enterprise-level funding, coupled with a recent major strategic investment, signals a strong growth trajectory for AvoMD. This capital infusion is expected to accelerate product development, expand market reach, and further enhance its AI capabilities within the healthcare sector. The company is poised to deepen its integration with healthcare systems, driving efficiency and improving patient care through advanced clinical decision support and workflow automation.
See full avoMD company page
